The Hepatocyte Growth Factor pipeline drugs market research report outlays comprehensive information on the Hepatocyte Growth Factor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Hepatocyte Growth Factor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Cardiovascular, Gastrointestinal, and Oncology which include the indications Amyotrophic Lateral Sclerosis, Diabetic Peripheral Neuropathy, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Liver Fibrosis, Ulcers, Ovarian Cancer, and Melanoma. It also reviews key players involved in Hepatocyte Growth Factor targeted therapeutics development with respective active and dormant or discontinued products.
The Hepatocyte Growth Factor pipeline targets constitutes close to 18 molecules. Out of which, approximately 18 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 5, 2, 2, 7, and 1 respectively.
Hepatocyte Growth Factor overview
Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor. It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing. In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals.
For a complete picture of Hepatocyte Growth Factor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
